

# Case Report: Excellent long survival of a female patient with Osteosarcoma still alive after 21 years' management in Babil Oncology Center (1998-2019)

<sup>1</sup>Dr. Sharif Fadhil Al-Alawachi, <sup>2</sup>Dr. Abud Al Wahab Al-Tahan, <sup>3</sup>Dr. Hussein Abdulzahra Hussein, <sup>4</sup>Dr. Mohammed Saeed Shareef Fadhil Fadhil, <sup>5</sup>Dr. Ph. Lamyaa Jaber Hassan, <sup>6</sup>Dr. Ali Shareef Fadhil Fadhil

**ABSTRACT**--30 years old unmarried girl with above knee amputation of right lower limbs since 1998 as radical treatment for Osteosarcoma of upper tibia with no systemic or local recurrence after oncological treatment till now.

**Keywords**-- Excellent long survival of a female patient with Osteosarcoma still alive after 21 years' management in Babil Oncology Center

## I. HISTORY OF PRESENT ILLNESS

The condition start before 21 years when she felt pain & swelling in her right foot, on examination we suspect bone tumor as by x ray there was periosteal reaction ,in the 2<sup>nd</sup> metatarsal bone with destruction of the cortex, operation was done (Excisional biopsy) to excise 2<sup>nd</sup> metatarsal bone as a whole with tumor sent for Histopathology which reveal Osteosarcoma , so we decided to do amputation of the right foot (above ankle) but the relative refused to do amputation.

After 9 months she came to Dr. Wahab Al-Tahan with another lesion in same side of the limb but in the upper third of right tibia with lytic lesion & destruction of the cortex so bone metastases suspected & another biopsy done & same result of Osteosarcoma proved, so we decided it do above knee amputation after complete survey if there was another metastases which was negative, so amputation done & sent for histopathology & also the result was **Osteosarcoma** after that the surgeon sent her to Dr. Sharif Fadhil for chemotherapy & she received 6 course of chemotherapy (ADM 50mg/m<sup>2</sup>& cisplatin 50mg/m<sup>2</sup> & every 3 weeks) followed closely by him for recurrence but till now there are no sign of metastases locally or distally.

---

<sup>1</sup> Consultant Clinical Oncologist, Director of Imam Sadiq Hospital Oncology Center, Merjan Medical City Babylon Oncology Center, Al-Amal Al-watiny Hospital - Baghdad, sh1956fa@yahoo.com , Mobile: 009647801006846

<sup>2</sup> Orthopedic surgeon, M.B.Ch.B. D. Orthopedic, Al-Hillah Teaching & Al-Salam Hospitals, altahhan55@yahoo.com , Mobile: 07816089313

<sup>3</sup> Medical Senior In Family Medicine (M.B.Ch.B., D.F.M.) dr.hussain966@yahoo.com , Mobile: 07805720728

<sup>4</sup> M.B.Ch.B , 2nd year Iraqi Board Histopathology, saeed199045@yahoo.com, Mobil : 07802571500

<sup>5</sup> Chemotherapy Pharmacological Senior, (Diploma in clinical pharmacy), dr.hussain966@yahoo.com Mobile: 07601373015,

<sup>6</sup> M.B.Ch.B, alisharif932008@gmail.com, Mobil: 07903590794

## II. BACKGROUND

Osteosarcoma is the commonest malignant tumor of bone<sup>(1,2)</sup>. It is till now not fully understood despite being a very old disease. Osteosarcoma is believed to be formed from the primitive mesenchymal cells that form the bone, and it is characterized histologically by the formation of malignant osteoid. The presence of other cell types might also be found, as these kinds of cells may also form from pleuripotential mesenchymal cells. However, the diagnosis of osteosarcoma is confirmed by the observation of any area of malignant bone.

Osteosarcoma is considered a deadly form of musculoskeletal tumors and the commonest cause of death is from lung metastasis<sup>(3,4)</sup>. The majority of osteosarcomas appear as a single lesion within the rapidly growing parts of the long bones in the pediatric age group. The usually affected parts are the distal femur, the proximal tibia, and the proximal humerus, but theoretically it can affect any bone.

## III. PATHOPHYSIOLOGY

Osteosarcoma is a tumor that affects bones which can affect any bone. It commonly affects the ends of long bones near metaphyseal growth plates. The most popular sites are as follows:

- Distal Femur
- Proximal Tibia
- Proximal Humerus
- Skull and jaw
- Pelvis

There are different types of osteosarcoma, such as conventional types (osteoblastic, chondroblastic, and fibroblastic), telangiectatic, multifocal, parosteal, and periosteal.

In this paper we only discuss conventional osteosarcoma (which is usually called simply as Osteosarcoma).

The etiology of tumors is still unknown<sup>(3,4,5,6,7)</sup> but probable causes involve: genetically inherited mutations, exposure to radiation & trauma, but in the majority of cases there is no identifiable cause.

Malignant tumors that arise in the bones are called primary bone tumors. While tumors that arise firstly in another area of the body (for example the breast or colon) are not called bone tumors.

There are many types of tumors that have the ability to metastasize and affect the bone as a secondary area including: Breast, Kidney, Lung, Prostate, Thyroid, usually these types affect old patients.

## IV. EPIDEMIOLOGY

In USA, 400 new cases per year were reported, with an overall 5 years survival rate of 63%. Cases reported in blacks are more than in whites. It is slightly more common in males than females, while it is very rare in the pediatric age group. However, case incidence increases with age with a significant increase in adolescence in relation with growth spurt in adolescence.

## V. PROGNOSIS

The prognosis of osteosarcoma depends on many factors including staging , tumor makers , and response to chemotherapy .

According to SEER data for 1973-2004, the overall relative 5-year survival rates were as follows <sup>[8]</sup> :

- Age < 25 years - 61.6%
- Age 25-59 years - 58.7%
- Age 60-85+ years - 24.2%
- Pulmonary metastases had reported more commonly with patients diagnosed with an elevated Alkaline Phosphatase (ALP) , in addition , an elevated LDH is associated with poor prognosis.

## VI. COMPARATIVE STUDIES

### *1-Survival in high-grade osteosarcoma: improvement over 21 years at a single institution.*<sup>(10)</sup>

12 years Follow up of patients revealed that approximately half (50%) are alive, with about 80% of them are free from disease.

Statistics showed that Survival has improved nowadays , despite of there is no new medications for osteosarcoma. Aggressive management are advised even for poor prognosis patients.

### *2-Trends and variability in survival among patients with osteosarcoma: a 7-year update* (11)

a score was developed to predict the prognosis which involved : age < 10 years , being a male, diameter of the tumor < 15 cm , osteoblastic or chondroblastic type , symptoms 2 months or less , and femur or humerus affected. Patient with 5 or 6 of these factors supposed to have a poor prognosis , while 2 or less had a good prognosis.

### *3-Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience* (12)

Survival rate was about three forth and approximately 70% at 5 and 10 years, respectively, with disease-free survival about 70% and 69%.

The local recurrence risk in femur tumors is as 5 times higher as tumors of other places. however , the risk is about 3 times much higher in proximal rather than in distal part of the femur.

Incomplete response to chemotherapy may lead to five times more risk of failure than whom with complete response to chemotherapy . Even in those patients with minimal or no necrosis in the primary tumor, ultimately 62% and 54% were disease-free at 5 and 10 years, respectively.

### *4-Survival Data for 648 Patients with Osteosarcoma Treated at One Institution*(13)



Survival is significantly influenced by age. The survival rate of patients who are 20 years or less was 78% , while the rate of whom 20-40 years was 70%.


## VII. CONCLUSION



Osteosarcoma case was registered for the patient (Roa Muhammad) 9 years old in 1998 & She is alive for 21 years became a 30 -years-old in 2019 in Babil province from 18686 case of a malignant tumor During the period (1990 -2018) 10052 (53.79%): women 8634 (46.20%) males, With ratio 1.15: 1 for women: men




After a referral from Respected brother: Dr. Abdul Wahab Al-Tahan , As he was found positive malignant tumor bone (Osteosarcoma) by excisional Biopsy of 2nd metatarsal bone of Rt foot ,then he did amputation above knee after 9 months as the tumor recurrence metastasized in ipsilateral upper tibia as her relative refused amputation from the start. then treated by 6 courses chemotheapy (Cisplatin + Adriamycin) every 3 weeks and she responded well to the treatment of the tumor did not spread to other organs of the body through regular check-up since 1998 until now (2019).













## REFERENCES

1. Orthopedic surgery options for the treatment of primary osteosarcoma.
2. Cancer Control. 2008; 15(1):13-20 (ISSN: 1073-2748)Marulanda GA; Henderson ER; Johnson DA; Letson GD; Cheong DOsteosarcoma and its variants.
3. Orthop Clin North Am. 1996; 27(3):575-81 (ISSN: 0030-5898)Vander Griend RA
4. Peltier LF. Tumors of bone and soft tissues. Orthopedics: A History and Iconography. San Francisco: Norman Publishing; 1993. 264-91.
5. Campanacci M. Preface. Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology and Treatment. 2nd ed. New York: Springer-Verlag; 1999.
6. Pochanugool L, Subhadharaphandou T, Dhanachai M, et al. Prognostic factors among 130 patients with osteosarcoma. Clin Orthop Relat Res. 1997 Dec. 345:206-14.
7. Tsuchiya H, Tomita K. Prognosis of osteosarcoma treated by limb-salvage surgery: the ten-year intergroup study in Japan. Jpn J Clin Oncol. 1992 Oct. 22(5):347-53.
8. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990 Dec. 8(12):1988-97.
9. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1. 115 (7):1531-43.
10. Song WS, Kong CB, Jeon DG, Cho WH, Kim MS, Lee JA, et al. Prognosis of extremity osteosarcoma in patients aged 40-60 years: a cohort/case controlled study at a single institute. Eur J Surg Oncol. 2010 May. 36 (5):483-8.
11. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
12. P. Picci, M. Mercuri, S. Ferrari, M. Alberghini, A. Briccoli, C. Ferrari, E. Pignotti, G. Bacci Ann Oncol (2010) 21 (6): 1366-1373. 04 November 2009\_ Istituto Ortopedico Rizzoli, Bologna, Italy. piero.picci@ior.it
13. Trends and variability in survival from osteosarcoma.
14. (PMID:280739) Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ Mayo Clinic Proceedings [1978, 53(11):695-700]
15. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience
16. Dale B, Glasser MS, MPHIL, Joseph M. Lane MD, Andrew G. Huvos MD, Ralph C. Marcove MD, Gerald Rosen MD Memorial Sloan-Kettering Cancer Center, New York, New York.
17. Survival Data for 648 Patients with Osteosarcoma Treated at One Institution.
18. Mankin, Henry J MD\*; Hornicek, Francis J MD, PHD\*; Rosenberg, Andrew E MD†; Harmon, David C MD‡; Gebhardt, Mark C MD\* Clinical Orthopaedics & Related Research: December 2004 - Volume 429 - Issue - pp 286-291. From the Departments of Orthopaedic Oncology, Medical Oncology, and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA